Anavex Life Sciences Corp (AVXL)

[falconer66a]

The Rett trial will end before 2022 (https://www.clinicaltrials.gov/ct2/show/NCT04304482). That CNS disease will then be treated with blarcamesine, showing that blarcamesine fixes otherwise recalcitrant CNS dysfunctions. That will elevate the AVXL share price, many months before the Alzheimer's study is completed and the FDA then approves blarcamesine for that big disease.

Check my posting. I referred to the "Alzheimer’s/CNS play," not just Alzheimer's alone. A single blarcamesine success for any of the three it's being tested on, Rett syndrome, Parkinson's disease dementia, or Alzheimer's, will validate the drug and the company. No stopping either the share price or corporate revenues thereafter.